Jiangxi Dongfeng Pharmaceutical Co., Ltd
Overview
Pharmaceutical manufacturing site surfaced via EU GMP non-compliance screening (EudraGMDP).
API / Drug Master Files
Jiangxi Dongfeng Pharmaceutical Co., Ltd holds 34 active (39 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.
- OPICAPONEActive2025-11-24
- ROXADUSTATActive2025-11-24
- ZINC GLUCONATEActive2025-09-11
- CALCIUM GLUCONATE FOR INJECTIONActive2025-09-11
- CALCIUM GLUCONATE FOR ORAL USEActive2025-09-11
- FERROUS GLUCONATEActive2025-09-11
- AZILSARTANActive2024-09-17
- AZILSARTAN KAMEDOXOMILActive2024-06-28
- DAPAGLIFLOZIN (AMORPHOUS)Active2024-06-05
- CRISABOROLEActive2024-05-30
- VONOPRAZAN FUMARATEActive2024-05-16
- CALCIUM GLUCONATE AND ZINC GLUCONATEActive2024-05-13
- CANAGLIFLOZIN HEMIHYDRATEActive2023-09-27
- EDOXABAN TOSILATEActive2023-09-20
- EMPAGLIFLOZINActive2022-11-02
Showing 15 of 39 Drug Master Files.
FDA compliance signals
1 FDA enforcement record linked to this company.
- eu_noncompliance2019-10-17
EU GMP Statement of Non-Compliance
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.